Recomendaciones basadas en la evidencia para el tratamiento preventivo de la migraña episódica. Asociación Colombiana de Neurología

Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. https://doi.org/10.1177/0333102417738202

Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L, et al. Prevalence of migraine in Latin America. Headache. 2005;45(2):106-17. https://doi.org/10.1111/j.1526-4610.2005.05024.x

Rubio AC, Arciniegas JA, Bolanos-Lopez JE, Gonzalez FJ, Gomez D, Mesa A, et al. Epidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022. J Headache Pain. 2024;25(1):226. https://doi.org/10.1186/s10194-024-01918-9

Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71(11):848-55. https://doi.org/10.1212/01.wnl.0000325565.63526.d2

Burshtein R, Burshtein A, Burshtein J, Rosen N. Are episodic and chronic migraine one disease or two? Curr Pain Headache Rep. 2015;19(12):53. https://doi.org/10.1007/s11916-015-0529-5

Sacco S, Ashina M, Diener HC, Haghdoost F, Lee MJ, Monteith TS, et al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45(2):3331024251320608. https://doi.org/10.1177/03331024251320608

Pradilla OE, Martínez JD, Rueda-Sánchez M, Sobrino F, Jiménez JD, Ramírez SF, et al. Recomendaciones de la Asociación Colombiana de Neurología para el uso de anticuerpos monoclonales antiCGRP en la profilaxis de migraña. Acta Neurol Colomb. 2022;38(supl. 1):1-22. https://doi.org/10.22379/24224022401

Prasad M. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clin Epidemiol Glob Health. 2024;25:101484. https://doi.org/10.1016/j.cegh.2023.101484

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71

Otto CM, Abdullah AR, Davis LL, Ferrari VA, Fremes S, Mukherjee D, et al. 2025 ACC/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(8):e359-70. https://doi.org/10.1161/CIR.0000000000001383

Børgesen SE, Nielsen JL, Møller CE. Prophylactic treatment of migraine with propranolol. Acta Neurol Scand. 1974;50(5):651-6. https://doi.org/10.1111/j.1600-0404.1974.tb02810.x

Pradalier A, Serratrice G, Collard M, Hirsch E, Feve J, Masson M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9(4):247-53. https://doi.org/10.1046/j.1468-2982.1989.0904247.x

Silberstein SD. Preventive migraine treatment. Continuum. 2015;21(4):973-89. https://doi.org/10.1212/con.0000000000000199

Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Kristensen TN, et al. Prophylactic treatment of classical and non-classical migraine with metoprolol--a comparison with placebo. Cephalalgia. 1983;3(4):207-12. https://doi.org/10.1046/j.1468-2982.1983.0304207.x

Kangasniemi P, Andersen A, Andersson P, Gilhus N, Hedman C, Hultgren M, et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia. 1987;7(4):231-8. https://doi.org/10.1046/j.1468-2982.1987.0704231.x

Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1988;28(1):15-23. https://doi.org/10.1111/j.1365-2524.1988.hed2801015.x

Ranganathan L, Ramamurthy G, Kanthimathinathan S. Preventive oral treatment of episodic migraine: an overview. Neurol India. 2021;69(supl.):S51-8. https://doi.org/10.4103/0028-3886.315985

Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention a randomized controlled trial. JAMA. 2004;291(8):965-73. https://doi.org/10.1001/jama.291.8.965

Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache. 2007;47(1):13-21. https://doi.org/10.1111/j.1526-4610.2007.00648.x

Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31(1):18-30. https://doi.org/10.1177/0333102410372427

Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44(4):647-51. https://doi.org/10.1212/wnl.44.4.647

Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):281-6. https://doi.org/10.1001/archneur.1995.00540270077022

Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48(2):210-20. https://doi.org/10.1111/j.1526-4610.2007.00949.x

Mentenopoulos G, Manafi T, Logothetis J, Bostantzopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia. 1985;5(supl. 2):135-40. https://doi.org/10.1177/03331024850050s225

Sørensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6(1):7-14. https://doi.org/10.1046/j.1468-2982.1986.0601007.x

Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry. 1973;36(4):684-90. https://doi.org/10.1136/jnnp.36.4.684

Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36(11):965-9. https://doi.org/10.1001/archneur.1979.00500470065013

Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51(1):33-51. https://doi.org/10.1111/j.1526-4610.2010.01800.x

Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523-32. https://doi.org/10.1177/0333102413515348

Øie LR, Wergeland T, Salvesen Ø, Bruvik Gravdahl G, Aschehoug I, Gulati S, et al. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2025;24(10):817-27. https://doi.org/10.1016/s1474-4422(25)00269-8

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-8. https://doi.org/10.1001/jamaneurol.2018.1212

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-54. https://doi.org/10.1177/0333102418779543

Hu B, Li G, Li X, Wu S, Yu T, Li X, et al. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain. 2022;23(1):90. https://doi.org/10.1186/s10194-022-01458-0

Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. https://doi.org/10.1016/s0140-6736(20)32544-7

Kitamura S, Matsumori Y, Yamamoto T, Ishikawa T, Hoshino Y, Yoshimatsu H, et al. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: a double-blind, randomized controlled trial. Headache. 2025;65(8):1403-12. https://doi.org/10.1111/head.14995

Kudrow D, Croop RS, Thiry A, Lipton RB. A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache. 2026;66(2):407-16. https://doi.org/10.1111/head.15002

Bhardwaj R, Morris B, Matschke KT, Bertz R, Croop R, Liu J. Characterization of rimegepant drug-drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam. Headache. 2025;65(2):291-302. https://doi.org/10.1111/head.14836

Edvinsson L. Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence. Expert Rev Neurother. 2024;24(12):1141-55. https://doi.org/10.1080/14737175.2024.2434079

Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727-37. https://doi.org/10.1016/s1474-4422(20)30234-9

Ailani J, Lipton R, Goadsby P, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl Med. 2021;385(8):695-706. https://doi.org/10.1056/nejmoa2035908

Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nežádal T, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024;23(4):382-92. https://doi.org/10.1016/s1474-4422(24)00025-5

Barbanti P, Egeo G, Pistoia F, Aurilia C, Scatena P, Rinalduzzi S, et al. GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures. J Headache Pain. 2025;26(1):122. https://doi.org/10.1186/s10194-025-02068-2

Singh A, Balasundaram MK. Atogepant for migraine prevention: a systematic review of efficacy and safety. Clin Drug Investig. 2022;42(4):301-8. https://doi.org/10.1007/s40261-022-01130-0

Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333-41. https://doi.org/10.1111/head.14692